



Recent Therapeutic Role of Natural Molecules against Alzheimer's Disease

Guest Editors:

Prof. Dr. Ilkay Erdogan Orhan

Department of Pharmacognosy,
Faculty of Pharmacy, Gazi
University, Ankara 06330, Turkey

Dr. Fatma Sezer Senol Deniz

Department of Pharmacognosy,
Faculty of Pharmacy, Gazi
University, 06330, Ankara, Turkey

Deadline for manuscript
submissions:

closed (21 December 2022)

Message from the Guest Editors

Dear Colleagues,

Neurodegenerative diseases are among the most common of deadly diseases around the world. In particular, Alzheimer's disease (AD), which is the most common type of dementia, is progressive in nature. It is characterized by memory deficit and abnormality in behaviors as well as social skills. AD patients also frequently require extensive pharmaceutical care. Unfortunately, there is currently no cure for this disease, and only symptomatic treatment is available. Due to the complex pathophysiology of AD, no distinct pharmacotherapy has been discovered to date. Cholinesterase inhibitors as well as NMDA receptor antagonists are the drugs most prescribed at present. Thus, a certain need for novel, effective, and safe drugs still exists. A large number of ongoing studies are aimed toward finding new anti-AD drugs of natural or chemical origins.

This Special Issue aims to scrutinize the capacity of natural molecules to serve as novel drug candidates with the ultimate aim of curing Alzheimer's disease by acting through various mechanisms. For this Special Issue, original research articles and reviews are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com